Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Sandra L Close"'
Autor:
Jean-Sébastien Hulot, Dirk Sibbing, Jean-Philippe Collet, Guillaume Paré, Stephen D. Wiviott, Tabassome Simon, Sandra L Close, Matthew J. Price, Jessica T. Delaney, Elliott M. Antman, Scott S. Sundseth, Michael Man, Jessica L. Mega, Marc S. Sabatine, Suman Duvvuru, Dietmar Trenk, Joseph R. Walker, Sabina A. Murphy
Publikováno v:
Journal of Thrombosis and Thrombolysis
Journal of Thrombosis and Thrombolysis, Springer Verlag (Germany), 2016
Journal of Thrombosis and Thrombolysis, 2016
Journal of Thrombosis and Thrombolysis, Springer Verlag (Germany), 2016
Journal of Thrombosis and Thrombolysis, 2016
Clopidogrel and prasugrel are antiplatelet therapies commonly used to treat patients with cardiovascular disease. They are both pro-drugs requiring biotransformation into active metabolites. It has been proposed that a genetic variant Q192R (rs662 A>
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a9a5777dd3dbf0267ee4f4cc380ddba
https://hal.sorbonne-universite.fr/hal-03020944
https://hal.sorbonne-universite.fr/hal-03020944
Autor:
S. Fossceco, L. O'Brien, Joe G.N. Garcia, Ivor S. Douglas, Jonathan Janes, Mark D. Williams, Jean Louis Vincent, Gordon R. Bernard, M. Man, Amy G Leishman, Andrew D. Shaw, Didier Payen, Robert J. Kaner, Sandra L Close
Publikováno v:
The Pharmacogenomics Journal. 13:218-226
Management of severe sepsis, an acute illness with high morbidity and mortality, suffers from the lack of effective biomarkers and largely empirical predictions of disease progression and therapeutic responses. We conducted a genome-wide association
Autor:
Nagy A. Farid, Kenneth J. Winters, Joseph R. Walker, Fanni Natanegara, Joseph A. Jakubowski, Ronan P. Kelly, Lei Shen, David S. Small, Sandra L Close, Mary Ho
Publikováno v:
British Journal of Clinical Pharmacology. 73:93-105
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Observations from clinical studies have demonstrated that: • CYP2C19 genotype does not have a clinically relevant effect on active metabolite concentrations or platelet inhibition in prasugrel-treated subjec
Autor:
Sandra L Close
Publikováno v:
Fundamental & Clinical Pharmacology. 26:19-26
Pharmacogenetics have been touted as the future of personalized medicine where genetic biomarkers will guide therapeutic approach. The currently approved thienopyridines, prasugrel and clopidogrel, are prodrugs requiring conversion to active metaboli
Publikováno v:
Cardiovascular Therapeutics. 30:e174-e182
Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimiz
Autor:
Sandra L Close, Stuart Hobbs, Lawrence J. Lesko, Michael Pacanowski, Linda Surh, Arlene R Hughes, Susanne B. Haga, Nadine Cohen, Michael Mosteller, Scott Gottlieb, Marisa Papaluca-Amati, Myong-Jin Kim, Scott D. Patterson, Issam Zineh, Bryan Dechairo
Publikováno v:
Pharmacogenomics. 11:1637-1647
The 2010 US FDA–Drug Industry Association (DIA) Pharmacogenomics (PGx) Workshop follows a series that began in 2002 bringing together multidisciplinary experts spanning regulatory authorities, medical research, healthcare and industry. This report
Autor:
Ansar Jawaid, Timothy W. Robison, Sandra L Close, Ian Hunt, Sharada Louis Truter, Huixiao Hong, Catherine Cornu-Artis, Michael E. Burczynski, Laurent Essioux, Li Zhang, Peter Morrow, Weida Tong, Federico Goodsaid, Rosane Charlab, Issam Zineh, Shashi Amur, Lois Hinman, Lawrence J. Lesko, James T. Mayne, David Laurie, Kevin Carl, David Jacobson-Kram, Jacky Vonderscher, Jiri Aubrecht, Jennifer Catalano, Ina Schuppe-Koistinen, Marisa Papaluca-Amati, Leming Shi, Albert J. Fornace, Heng-Hong Li, Klaus Lindpaintner, Olivia Spleiss, Agnes Westelinck, John Roth
Publikováno v:
Nature Reviews Drug Discovery. 9:435-445
Heterogeneity in the underlying mechanisms of disease processes and inter-patient variability in drug responses are major challenges in drug development. To address these challenges, biomarker strategies based on a range of platforms, such as microar
Autor:
Elliott M. Antman, Lei Shen, Stephen D. Wiviott, William L. Macias, Eugene Braunwald, John T. Brandt, Marc S. Sabatine, Sandra L Close, Joseph R. Walker, Richard D. Hockett, Jessica L. Mega
Publikováno v:
Circulation. 119:2553-2560
Background— Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes. Among persons treated with clopidogrel, carriers of reduced-function CYP2C19 alleles have significantly lower levels of act
Autor:
Agneta Siegbahn, Stefan James, John T. Brandt, Christoph Varenhorst, Michael Man, David Erlinge, Oscar Ö. Braun, Joseph R. Walker, Lars Wallentin, Kenneth J. Winters, Sandra L Close
Publikováno v:
European Heart Journal
Aims The metabolic pathways leading to the formation of prasugrel and clopidogrel active metabolites differ. We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Me
Autor:
Stephen D. Wiviott, Richard D. Hockett, Marc S. Sabatine, William L. Macias, Joseph R. Walker, Elliott M. Antman, John T. Brandt, Jessica L. Mega, Lei Shen, Eugene Braunwald, Sandra L Close
Publikováno v:
New England Journal of Medicine. 360:354-362
Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function.We tested the association bet